Parabilis Medicines, Inc. Common Stock (PBLS)

• Market cap: $3.06B
• 1 day: 0.16%
• 5 days: -24.89%
• 1 month: -20.73%
• 3 months: -20.73%
• 6 months: -20.73%
• Year to date: -20.73%
• 1 year: -20.73%
• 5 years: -20.73%
• 10 years: -20.73%
• Sector: Healthcare
• Industry: Biotechnology

About: Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.